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Abstract
Background: Prior to nonmedical cannabis legalization in Canada, individuals were 
only able to access cannabis legally through licensed producers with medical au-
thorization. Now with an additional legal access system designed for nonmedical 
purposes, it is unclear what factors influence cancer survivors’ decisions to medi-
cate or not medicate cannabis as a complementary therapy to alleviate their cancer 
symptoms.
Methods: We recruited cancer survivors via social media. Interested individuals 
were purposively sampled to ensure maximization in terms of age, sex, and province 
of residence. Constructs of the Theory of Planned Behavior were explored during 
the telephone interviews as participants described what influenced their decisions to 
medicate or not medicate cannabis to manage their symptoms.
Results: Interviews were conducted with 33 cancer survivors. All individuals be-
lieved that cannabis would manage their cancer symptoms. Those that chose to medi-
cate with cannabis provided a variety of reasons, including that cannabis was a more 
natural alternative; that it reduced their overall number of prescription drugs; and 
that safer products had become available with the legalization of nonmedical can-
nabis. Some individuals also indicated that support from physicians and validation 
from family and friends were important in their decision to medicate with cannabis. 
Individuals who opted not to medicate with cannabis raised concerns about the lack 
of scientific evidence and/or possible dependency issues. Some also felt their physi-
cian's disapproval was a barrier to considering cannabis use.
Conclusions: The findings revealed that recreational legalization made using can-
nabis appear safer and easier to access for some cancer survivors. However, physi-
cians’ censure of cannabis use for symptom management was a barrier for survivors 
considering its use.
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1 |  INTRODUCTION
Cancer survivors––individuals diagnosed with cancer until 
the end of their life1––have reported medicating with canna-
bis or drugs containing cannabinoid.2 They report favorable 
outcomes for managing chemotherapy-induced nausea and 
vomiting, cancer-related pain, anorexia, insomnia, and de-
pression,3,4 as well as an improvement in their quality of life.5 
While there are a limited number of high-quality clinical tri-
als evaluating the effectiveness of cannabis in alleviating can-
cer symptoms,6,7 some countries have legalized nonmedical 
cannabis. In Canada, the Cannabis Act8 (effective as of 17 
October 2018), which replaced the Access to Cannabis for 
Medical Purposes Regulations,8 enables individuals to pur-
chase cannabis and cannabinoid products through licensed 
producers for personal use without medical documentation.
The Canadian Medical Association (CMA) has recog-
nized the unique requirements of individuals suffering from 
chronic diseases––including cancer––for which conventional 
therapies have not been effective and for whom cannabis may 
provide relief.9,10 However, the CMA raises concerns about 
the lack of evidence on the risks and benefits associated with 
the use of cannabis. The CMA believes that physicians should 
not be gatekeepers because cannabis has not undergone the 
established regulatory review processes that are required for 
all prescription medicines. Oncology health-care providers 
reported that they lacked sufficient cannabis knowledge to 
make recommendations to their patients.11 The lack of read-
ily accessible information in standard medical textbooks 
regarding dosing requirements and potential side-effects of 
cannabis use may make it challenging for physicians when 
advising their patients.
The recent full legalization of nonmedical cannabis in 
Canada may result in cancer survivors opting to medicate 
their cancer symptoms without guidance from health-care 
providers.12 However, there have been limited studies deter-
mining the frequency of cannabis use among cancer patients 
in Canada.13-16 A 2017 survey of cancer patients in the prov-
ince of Alberta revealed that 43% had tried cannabis.15 In 
British Columbia (BC), a 2018 cross-sectional study showed 
that 23% of cancer patients were currently using canna-
bis-based products to manage their symptoms or treat their 
cancer, or both; 31% of these individuals had medical autho-
rization.16 These few studies further contribute to the prob-
lem of insufficient evidence regarding the risks and benefits 
of medicating with cannabis.
It is vital to better inform health-care providers to support 
their patients regarding cannabis medication and to promote 
person-centered and informed decision making. In Canada, 
we have a unique opportunity to study the impact of coun-
try-wide recreational legalization of access to nonmedical 
cannabis on cancer survivors’ attitudes toward use of those 
substances. The aim of the current interview study was to 
gain an understanding of the factors that influence cancer 
survivors’ decisions to medicate or not medicate with can-
nabis as a complementary therapy to alleviate their cancer 
symptoms.
2 |  METHODS
2.1 | Recruitment
Canadian cancer survivors were recruited using social media 
to participate in this interview study by first completing an 
online eligibility survey to express their willingness to par-
ticipate in the interview. The study was advertised on Twitter 
and Facebook using our investigators’ channels, as well 
as several cancer organizations (e.g., Canadian Centre for 
Applied Research in Cancer Control, BC Cancer) that sup-
ported our recruitment efforts. For the purpose of this study, 
we used the National Cancer Institute's (NCI) definition of a 
cancer survivor, which is an individual from the time of diag-
nosis until the end of life.17 The rationale for using the NCI’s 
definition was to capture individuals’ experiences across the 
cancer care continuum. In the eligibility survey, individuals 
provided information about their sex, age, province/territory 
of residence, month/year of cancer diagnosis, type of can-
cer, and whether or not cannabis was used to medicate cancer 
symptoms or treatment side-effects. The recruitment period 
was from September 2019 to November 2019. The study pro-
tocol was approved by the BC Cancer Research Ethics Board 
(H19-01489).
Of the 115 individuals who opened the eligibility survey, 
111 provided complete responses. The research team purpo-
sively sampled individuals to ensure maximization with re-
spect to age, sex, province/territory of residence, and whether 
or not cannabis was used to control or alleviate cancer symp-
toms or treatment side-effects. Of the 111 individuals who 
consented to be contacted to participate in the study, 46 indi-
viduals were sent an invitation email to schedule an interview 
time. Participants received an honorarium of $50 (CAD).
2.2 | The Theory of Planned 
Behavior and the interview process
An interview guide (available as an electronic Supplementary 
material) was developed informed by the Theory of Planned 
Behavior (TPB). Participants were asked to describe what 
influenced their decisions to manage their cancer symptoms 
with cannabis (Figure 1). The TPB is a well-validated, psy-
chological, theory-based, decision-making model that pro-
poses three constructs which together predict an individual's 
intention to perform a specific behavior.18 These constructs 
are attitudes (i.e., how positively (or negatively) a behavior 
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is appraised); subjective norms (i.e., perceived social pres-
sure to perform (or not perform) a behavior); and perceived 
behavioral control (i.e., perceived ease (or difficulty) of per-
forming a behavior). Influencing each of the three constructs 
are the associated underlying beliefs. Specifically, behavioral 
beliefs (i.e., advantages and disadvantages of performing the 
behavior) influence attitudes; normative beliefs (i.e., whether 
specific individuals approve or disapprove) underlie subjec-
tive norm; and control beliefs (i.e., barriers and facilitators) 
influence perceived behavioral control.
The interview questions were open-ended and probes 
were used when it was necessary to clarify responses or to 
gain more information. All interviews were conducted over 
the telephone by a trained interviewer (RM), and lasted be-
tween 14-60 minutes (average: 30 min). The interviews were 
digitally recorded and transcribed by a third party.
2.3 | Data analysis
The transcripts were de-identified, and analyzed using the 
initial codes based on the TPB structure and organized in 
NVivo software (QSR International Pty Ltd., Version 12, 
2019). A main qualitative analyst (HMC) read and coded all 
transcripts to get a comprehensive sense of the data, a second 
analyst (CB) independently read and coded approximately 
half of the transcripts (52%), and a third analyst (AR) read 
30% of the transcripts. Weekly norming sessions were held 
with the three analysts and the interviewer. The purpose of 
these sessions was to resolve disagreements in the inter-
pretation and coding of transcripts by group discussion and 
consensus; iteratively revise understandings of the data; and 
determine when new categories or concepts could be derived 
from the data. The main analyst kept an audit trail of cod-
ing decisions and meetings. The findings were stratified by 
participants reporting to medicate their cancer symptoms 
with cannabis (MWC) and those reporting that they do not 
medicate with cannabis (nMWC). By presenting stratified 
findings, a deeper understanding of the factors that influence 
medicating with cannabis could be gained.
3 |  RESULTS
3.1 | Study participants
Of the 46 individuals invited to the study, 33 cancer survivors 
participated (Table 1). The majority of the study participants 
were female (61%) and resided in either Ontario (30%) or BC 
(27%). The sample consisted of slightly more MWCs (52%) 
than nMWCs. The 13 individuals, who did not respond to 
our email invitation, did not provide reasons for declining 
F I G U R E  1  Schematic of theory of planned behaviour for individuals’ decision to medicate with cannabis
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participation. The majority of these individuals were female 
(85%), under the age of 40  years (62%), and were MWCs 
(69%).
3.2 | Findings from the interviews
In terms of behavioral beliefs, all participants believed that 
medicating with cannabis could help to manage cancer 
symptoms: “it was good for […] nausea; it was good for 
sleeping; it was good for depression, anxiety [;…] it was 
good for joint pain as well” (ID27, MWC). MWCs indi-
cated they opted to use cannabis to address issues of poly-
pharmacy, such that cannabis could replace one or many of 
their prescribed medications. While nMWCs perceived that 
cannabis had benefits to alleviating cancer symptoms, they 
firmly believed that medicating with cannabis would lead to 
undesired side-effects and possibly interact with their cur-
rently prescribed medications. For normative beliefs, family 
and friends were more likely than the medical community 
to approve of cannabis use. For control beliefs, both MWCs 
and nMWCs held the perceptions that easily accessible can-
nabis facilitates cannabis use. The most reported barrier 
among nMWCs was concern about possible dependency 
issues.
More detailed findings from each of the TPB constructs 
are described below.
3.2.1 | Behavioral beliefs
Not all participants made the decision to medicate with can-
nabis. For some nMWCs, the lack of cannabis information, 
including availability of different products (e.g., edibles), led 
them to perceive that the side-effects from taking cannabis 
were undesirable.
[…] I don't like anything in my lungs […]. And 
then the other reason was that I heard that peo-
ple had the munchies with it and I didn't want to 
keep eating because of [the cannabis].
(ID24, nMWC).
Some nMWCs stated that they felt cannabis was not neces-
sary as an initial approach to alleviate their cancer symptoms. 
One participant stated that she “[…] always had medications to 
turn to or other techniques” and recognized that she “[…] had 
a really complicated course of treatment with a lot of unusual 
side-effects and drug interactions [… and…] didn't think that 
adding an unknown [cannabis…] was a good idea […]” (ID2, 
nMWC).
Alternatively, participants who medicated with cannabis 
did not perceive cannabis to have significant side-effects on 
their health. A desire was observed among some MWCs to 
medicate their cancer symptoms with a “natural” substance 
“that grows [in the] wild, [as] it did for centuries” (ID7, 
MWC). There was a perception among some MWCs that 
cannabis can address issues of polypharmacy.
I actually refrained from using some of my che-
motherapy pills in exchange for marijuana, like 
the nausea pills.
(ID27, MWC).
T A B L E  1  Characteristics of the study sample
Count 
(%)
Sex
Male 13 (39%)
Female 20 (61%)
Current age (years)
<30 5 (15%)
30-44 9 (27%)
45-64 10 (30%)
>65 9 (27%)
Province of residence
British Columbia 9 (27%)
Alberta 6 (18%)
Ontario 10 (30%)
Quebec 2 (6%)
New Brunswick 1 (3%)
Nova Scotia 4 (12%)
Newfoundland 1 (3%)
Medicating cancer symptoms with cannabis
Yes 17 (52%)
No 16 (48%)
Most recent cancer diagnosis
Colorectal 6 (18%)
Breast 6 (18%)
Ovarian 5 (15%)
Lymphoma 3 (9%)
Leukemia 2 (6%)
Prostate 2 (6%)
Thyroid 2 (6%)
Gastric 1 (3%)
Germ 1 (3%)
Lung 1 (3%)
Multiple myeloma 1 (3%)
Neck 1 (3%)
Testicular 1 (3%)
Tongue 1 (3%)
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3.2.2 | Normative beliefs
Both MWC and nMWC participants reported a variety of in-
dividuals in their lives whose opinions were important to them 
regarding their decision to medicate their cancer symptoms 
with cannabis. The opinions held by these individuals affected 
the participants by: (a) influencing the level of support they 
received and (b) influencing their willingness to be open about 
medicating, or to consider medicating, with cannabis.
Family and friends. Many MWC and nMWC participants 
valued the opinions of family members and friends, even if 
their opinions were misinformed. Participants medicating 
with cannabis reported that family and friends were generally 
supportive of this practice. They reported that their family 
and friends held the hope that the cannabis “will help cure 
[… or provide] relief of [their cancer] symptoms” (ID13, 
MWC).
It was apparent that participants desired the approval from 
family and friends about medicating with cannabis. Different 
approaches were observed among participants with how they 
sought approval. One nMWC participant, for example, stated 
she would be open to her family members if she were to con-
sider cannabis for her cancer symptoms.
[…] I also am concerned, always, with what my 
family thinks and their sort of approval of me. 
So, I think I was just worried because they know 
that […] I’ve never tried cannabis, so I think 
maybe they may be concerned, like "Why? Why 
are you doing this now?”.
(ID4, nMWC).
Moreover, there were MWCs and nMWCs with strong de-
sires to gain the approval of their family that they made the 
decision to not fully disclose that they are medicating, or con-
sidering medicating, with cannabis. These participants had an 
underlying concern of their family's disapproval of cannabis.
[…] I kept [my medicating with cannabis] a se-
cret […] because I have children and I’m not too 
sure how they would react.
(ID6, MWC).
[…B]etween you and me, probably wouldn't 
mention [cannabis, if I decide to medicate with 
it] initially to my husband.
(ID24, nMWC).
Medical team. Both MWCs and nMWCs valued the opin-
ions of their medical team when making the decision to med-
icate cancer symptoms. They believed that their physicians 
“[…] know exactly what's happening [when…] they say 
that this drug works and that drug doesn't work […]” (ID15, 
nMWC). Because of this view, many nMWCs preferred that 
their medical team provided clinical guidance on medicating 
with cannabis.
If [medicating with cannabis] was recom-
mended to me or prescribed to me by my on-
cologist or anyone on her team then, you know, 
that to me would say they absolutely support its 
use and see that there is high value. The fact that 
they don't even raise the subject, you know, says 
to me they may have some concerns about the 
value.
(ID9, nMWC).
MWCs described different levels of approval their medical 
team had in regards to medicating with cannabis. Some physi-
cians were agreeable to a prescription for cannabis or a referral 
to a medical cannabis specialist but others were not. One par-
ticipant highlighted the challenge with accessing cannabis even 
though their medical team was supportive of cannabis.
The family doctor that I have is highly support-
ive of whatever works for me and makes me 
comfortable considering the circumstances. 
However, did not prescribe [cannabis], but she 
was very supportive but couldn't facilitate it, 
fine. Cancer doctor was also very open and very 
supportive [of medicating cancer symptoms 
with cannabis] but also […] doesn't deal with 
any of the prescription […].
(ID16, MWC)
Not all MWCs were willing to fully disclose that they were 
medicating with cannabis to their medical team because they 
recognized that their doctor would disapprove. One participant 
said that his “[medical team…] would never recommend that I 
do [cannabis…]. They don't like that I do it, so but they don't tell 
me not to either” (ID27, MWC). Another participant described 
the consequence of his doctor ever learning of his cannabis use.
My own personal physician that I've had for 
25 years said, “If you're using [cannabis] then 
you'd better find a new doctor because I won't 
see you anymore.” So I've had to hide it from 
him because otherwise he's kicking me out the 
door.
(ID14, MWC)
Both MWCs and nMWCs expressed that the medical 
team's disapproval also resulted in communication challenges 
if they wanted to have a discussion about cannabis at their 
appointments.
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[…W]hen I ask [… my doctor] about cannabis 
or anything she […] just put[s] her hands up in 
the air and stops me, and goes like “We can't 
talk about this.” So, literally there's a physical 
block of being able to talk about it, so that's 
weird to me.
(ID13, MWC)
[…] I went to my family doctor and […] I said, 
“What about cannabis?” And she said, “Oh, you 
don't want to get into that. That just creates more 
issues for you.” So she ditched it, so it was dead 
in its tracks.
(ID24, nMWC).
Society. Canada's legalization of nonmedical cannabis 
elicited mixed responses among the participants regardless of 
whether they medicated with cannabis or not. Some MWCs and 
nMWCs felt that cannabis should have always been legalized. 
However, for some MWCs and nMWCs, the legalization re-
moved the stigma of using cannabis.
[The legalization of cannabis] gives me a 
chance to remove the illegal, […] you could 
go to jail stigma attached to it. […] I just don't 
want to do something that the law says is in-
appropriate to do in our society. So the fact 
that cannabis has been legalized gives me an 
opportunity to feel comfortable about using it 
[…].
(ID24, nMWC).
For some participants, legalization had little impact on 
their decision-making process. For MWCs, they made the 
decision to medicate with cannabis before legalization. For 
some nMWCs, legalization did not change their willingness 
to medicate with cannabis due to their work obligations (i.e., 
international travel). One participant stated that “just be-
cause [cannabis is] legal doesn't mean that it's something for 
everyone at all times” (ID12, nMWC).
3.2.3 | Perceived behavioral control
A range of facilitators and barriers to medicating with can-
nabis was reported. The different modes of access were the 
most commonly reported facilitator to medicating with can-
nabis. Legalization has improved the accessibility of canna-
bis for some participants, who discussed the ease in accessing 
cannabis without “the hassle of like going through all that 
process [of obtaining a medical cannabis document]” (ID29, 
nMWC).
[…] I think [the legalization of cannabis] just 
made it more convenient, frankly, because it's a 
shit show trying to get your [cannabinoid] prod-
ucts through the medicinal sometimes […]. So 
it's the convenience to go down to the corner 
and grab pre-rolls, or flower, or oil, whatever 
you need, and now you'll be able to get edibles 
too.
(ID16, MWC).
The legalization of cannabis elicited a range of perceptions 
from the participants regarding the safety of the product they 
were using. Some expressed that there was now no need “to 
worry about [the cannabis’] quality” (ID18, MWC). Some par-
ticipants had no concerns about the safety of the cannabis prod-
uct before legalization.
I'll be frank with you; I don't buy it from a legal 
store […]. I have a private source. […T]his indi-
vidual makes other things from the weed that he 
buys. And the quality of the other products that 
he makes is very good […].
(ID7, MWC).
MWC participants expressed that cannabis products are 
available at different costs depending on how you choose 
to access them. One participant stated that she has kept her 
medicinal cannabis designation “because [my cannabis is] 
tax deductible and I've been approved for tax credits […]” 
(ID16, MWC). For many MWCs, they stated their preference 
was still to access cannabis from their private sources as they 
did before legalization because they can purchase it for “a 
lot less than what those stores are asking for” (ID7, MWC).
Participants needed to feel comfortable with experiment-
ing with cannabis to determine the right product and required 
dosage to help with their symptoms. One participant knew 
she was “[…] perfectly confident that you know your own 
body, you know when you felt good and you know you're 
having a reaction […]” (ID1, MWC). However, another par-
ticipant expressed hesitation about the amount of cannabis 
she was prescribed to use.
[…R]ight now I'm taking maybe like a lower 
amount of what the physician has prescribed be-
cause I'm waiting to gather some more informa-
tion and before starting what he recommended 
[…].
(ID21, MWC)
Participants had mixed perceptions about the ability to start 
and stop medicating with cannabis. nMWCs raised concerns 
about “dependency issues [… and did not want to] become 
heavily dependent on [cannabis…]” (ID2, nMWC). MWCs 
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stated that if they were asked to stop using cannabis that they 
were able to; however, only a few participants reported demon-
strated that they were able to stop medicating cannabis on cer-
tain occasions.
[…] I went on a couple international trips, so of 
course I didn't travel with any cannabis, and I 
had no issues sleeping without it.
(ID8, MWC).
4 |  DISCUSSION
Guided by the TPB and a strong sample size, this study gained 
an understanding of the motivations of Canadian cancer sur-
vivors who made the decision to medicate or not medicate 
their cancer symptoms with cannabis. Overall, study par-
ticipants generally reported favorable attitudes toward medi-
cating their cancer symptoms, such as pain and insomnia, 
with cannabis; this finding has been reported elsewhere.16 
Despite these perceived benefits, not all participants made 
the decision to manage their cancer-related health needs with 
cannabis.
The cancer survivors in the study were affected differently 
by their behavioral, normative, and control beliefs regarding 
medicating with cannabis. The importance of the constructs 
in predicting behavior appeared to be impacted by the level 
of experience the individual has had with cannabis. nMWCs 
wanted more information to address their concerns about 
unwanted side-effects and potential interactions with medi-
cations they are currently taking. Conversely, MWCs typi-
cally required no additional information because they already 
had strong perceptions of the benefits of cannabis, which 
included reduction of burden related to polypharmacy; this 
finding has also been reported elsewhere.16 Cost was a con-
cern for some MWCs but due to their experience, they were 
aware of the availability of options to purchase cannabis; this, 
in turn, provided them with a sense of control over how much 
they spent on cannabis.
The legalization of nonmedical cannabis in Canada played 
a role for some participants in their decision-making process. 
Legalization provided them with a sense of social acceptance 
and legitimacy for them to medicate with cannabis. This was 
reflected in their discussions of wanting to portray a desirable 
image of themselves, as well as to others. Furthermore, legal-
ization led them to feel that the quality control of cannabis 
had improved compared to products prior to legalization (i.e., 
consumed products have accurate labeling and do not contain 
molds or pesticides16). For individuals who had previously 
been medicating with cannabis long term, legalization had no 
impact. These individuals still preferred to obtain their canna-
bis from their private and unregulated sources at lower costs.
The normative beliefs held by individuals appear to have 
the greatest impact on whether they made the decision to 
medicate their cancer symptoms with cannabis. It was ap-
parent that many participants desired the approval of import-
ant individuals in their lives, especially their medical team, 
when making this decision. A mixed level of physician com-
fort discussing cannabis was observed. Some participants 
reported that their physicians were willing to facilitate ac-
cess to cannabis by writing a prescription or providing a 
referral to a medical cannabis expert. Moreover, some par-
ticipants reported frustration and dissatisfaction with their 
physicians’ lack of willingness to discuss cannabis as an 
option for managing their cancer symptoms; this potentially 
could have led some participants to be misinformed about 
medicating with cannabis (i.e., cannabis curing cancer).19 
However, some participants reported medicating with can-
nabis, despite not getting recommendations from their phy-
sicians, as their behavioral and control beliefs were stronger 
than their normative beliefs.
Physicians’ willingness to recommend cannabis to their 
patients may be dependent upon the policies set in place 
by their respective medical regulatory authorities (i.e., 
professional colleges). Many Colleges prohibit or strongly 
discourage dispensing, providing, or accepting delivery of 
cannabis for medical purposes, which likely impacts physi-
cians’ willingness to recommend cannabis for their patients. 
In addition, a recent study reported that oncology health-
care providers felt that they lacked the knowledge to rec-
ommend cannabis to their patients because they desired the 
ability to monitor their patients’ cannabis use and to pre-
scribe accurate doses11; as a result, physicians did not feel 
ready, and did not want to, answer patients’ questions about 
medical cannabis.20,21
To the best of our knowledge, this is the first study 
that applied the TPB to understand the impact of national 
legalization of cannabis on cancer survivors’ decision to 
medicate or not medicate with cannabis using qualitative 
methodology. While Victorson et al. explored attitudes of 
American cancer survivors regarding medical cannabis for 
their symptom management using focus groups,5 results 
from the United States (US) are difficult to interpret, as 
state-level legalization legislation remains in conflict with 
federal law.22 Thus, the legal status of cannabis remains 
ambiguous, and patients’ attitudes in the United States 
will be influenced by this ambiguity. That said, several of 
our findings were similar to those reported by Victorson 
et al. Similar findings included benefits for symptom 
management and side-effect relief, concerns regarding 
the social stigma with the image of using cannabis among 
their social circles, cost of cannabis, and worry about the 
legal consequences were raised; though for our study, the 
last point is now alleviated with the Canadian legaliza-
tion of nonmedical cannabis. While the burden related to 
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polypharmacy was not raised, Victorson et al. found that 
their study sample believed that cannabis was a safer al-
ternative to many conventional medications that they were 
prescribed.
Individuals with a range of tumor sites participated in 
the study; the most prevalent were colorectal and breast 
cancers, which aligned with the most recent Canadian can-
cer statistics.23 Lung and prostate cancers were the other 
most prevalent cancers in Canada but individuals diagnosed 
with lung and prostate cancers were under-represented in 
our study. Using social media to recruit study participants 
allowed us to gain a wide range of perspectives from can-
cer survivors in Canada. The participants, however, were 
primarily recruited from Ontario and BC, the two most 
populous provinces. While social media broadened the re-
cruitment coverage, we may have missed perspectives from 
individuals who do not have Internet access or do not fol-
low social media. Given the online nature of our recruit-
ment strategy, we relied on convenience sampling, which 
may lead to noncoverage bias in that the decision to par-
ticipate in the study is at the discretion of the individuals 
and we do not have means of knowing about those who 
do not participate.24 As all interviews were conducted in 
English, we may have missed out on important viewpoints 
of non-English speaking cancer survivors. We were able 
to gain nearly equal perspectives of MWCs and nMWCs 
to ensure that conversations were not highly in favor of 
medicating cancer symptoms with cannabis. In addition, 
our analysis highlighted the complexities that were faced 
by nMWC participants, who were considering cannabis for 
their cancer symptoms.
This study has shown that individuals affected by can-
cer positively perceived cannabis to alleviate symptoms 
such as pain, neuropathy, and insomnia. Our data revealed 
that, despite this favorable attitude toward cannabis, not 
everyone made the decision to medicate with cannabis. 
Individuals’ behavioral, normative, and control beliefs 
regarding medicating with cannabis provided vital infor-
mation on what motivated their uptake of cannabis. An in-
vestigation of the underlying beliefs regarding medicating 
with cannabis can provide information on what motivates 
this behavior and may offer important future research av-
enues, including optimizing follow-up cancer care. This 
information is important to health-care providers in can-
cer as they receive the professional training and formal 
education required to support and educate cancer patients 
and survivors to improve self-care, knowledge, and overall 
empowerment.
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